バイオシミラーの世界市場見通し2022:エリスロポエチン(EPO)、ヒト成長ホルモン(HGH)、顆粒球コロニー刺激因子(G-CSF)、モノクローナル抗体(mAb)、インスリン、インターフェロン(IFN)

◆英語タイトル:Global Biosimilar Market Outlook 2022
◆商品コード:DATA1122049
◆発行会社(調査会社):RNCOS
◆発行日:2016年9月
◆ページ数:135
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥162,000見積依頼/購入/質問フォーム
Multi UserUSD2,200 ⇒換算¥237,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートはバイオシミラーの世界市場について調査・分析し、バイオシミラーの世界市場規模、バイオシミラーの世界市場動向、関連企業分析などを含め以下の構成でお届けします。1. アナリストの見解
2. 調査方法
3. バイオシミラーの世界市場見通し2022
4. 市場動態(市場成長要因、市場課題、市場機会)
5. 製品種類別市場セグメンテーション
6. 地域別市場セグメンテーション
7. 用途別市場セグメンテーション
8. 市場動向
9. M&A動向
10. 市場環境分析
11. 競争状況(企業分析)
12. 未来展望
【レポートの概要】

A biosimilar is a biologic product that is similar to a regulatory body approved reference product, and has no clinically meaningful differences in terms of safety and effectiveness from that reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry. Furthermore, the recent approval of three biosimilars in the US market is providing an impetus to more biopharmaceutical companies to enter this field.

As per RNCOS report “Global Biosimilar Market Outlook 2022”, the global biosimilars market is anticipated to witness a high double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global biosimilars market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global biosimilars market.

The global biosimilars market has been segmented on the basis of type of product. The major types of biosimilars present in the market include monoclonal antibodies, erythropoietin, insulin, G-CSF, HGH, and interferon amongst others. The report also highlights the various biosimilar drugs available in the market, and the biosimilars currently in various phases of clinical trials.

Furthermore, the global biosimilars market has also been segmented on the basis of their applications. According to the report, oncology is expected to account for the largest share in 2016 due to presence of large number of biosimilars for this indication. Based on geography, the report divides the market into Europe, Asia-Pacific, North America and Rest of the World. In 2016, Europe is expected to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global biosimilars industry.

The last section of the report discusses about the prominent players in global biosimilars market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and clinical pipelines. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global biosimilars market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Global Biosimilars Market Outlook 2022
4. Market Dynamics
4.1 Drivers
4.1.1 Growing Geriatric Population
4.1.2 Entry of Biosimilars in the US Market
4.1.3 Ability to Curb Healthcare Cost
4.1.4 Rising Incidences of Chronic Diseases
4.1.5 Government Initiatives
4.2 Challenges
4.2.1 Regulatory Issues
4.2.2 Greater Litigation Risk
4.2.3 Lack of Standardized Manufacturing Process
4.3 Opportunities
4.3.1 Emerging Markets – Area of Opportunities for Biosimilars
4.3.2 Patent Expiry of Blockbuster Biologics
5. Market Segmentation by Product Type
5.1 Erythropoietin (EPO)
5.2 Human Growth Hormone (HGH)
5.3 Granulocyte- Colony Stimulating Factor (G-CSF)
5.4 Monoclonal Antibody (mAb)
5.5 Insulin
5.6 Interferon (IFN)
5.7 Others
6. Market Segmentation by Geography
6.1 Europe
6.1.1 Germany
6.1.2 France
6.1.3 Italy
6.1.4 Spain
6.1.5 UK
6.2 Asia-Pacific
6.2.1 India
6.2.2 China
6.2.3 Japan
6.3 North America
6.3.1 US
6.3.2 Canada
6.4 Rest of the World
7. Market Segmentation by Applications
7.1 Oncology
7.2 Blood Disorders
7.3 Others
8. Market Trends and Developments
8.1 Development of Modular Biosimilar Plants
8.2 Biosimilars in Oncology
9. Mergers and Acquisitions
10. Porter’s Five Forces Analysis
11. Competitive Landscape
11.1 Market Share of Major Players
11.2 Company Profiles
11.2.1 Biocad
11.2.2 Celltrion Inc.
11.2.3 Dong-A Socio Group
11.2.4 Pfizer Inc.
11.2.5 Intas Pharmaceuticals Ltd.
11.2.6 Sandoz International GmbH – A Novartis Company
11.2.7 Stada Arzneimittel AG
11.2.8 Teva Pharmaceutical Industries Ltd.
11.2.9 Amgen Inc.
11.2.10 Biocon
12. Future Outlook

List of Figures:

Figure 3-1: Global – Biosimilars Market (Million US$), 2016 & 2022
Figure 4-1: Global – Population above 60 Years (Billion), 2013 & 2050
Figure 4-2: World’s Best Selling Biologics and their Patent Expiry in the US & EU
Figure 5-1: Global – Biosimilars Market by Product Type (%), 2016
Figure 5-2: Global – Erythropoietin Biosimilars Market (Million US$), 2016 & 2022
Figure 5-3: Global – HGH Biosimilars Market (Million US$), 2016 & 2022
Figure 5-4: Global – G-CSF Biosimilars Market (Million US$), 2016 & 2022
Figure 5-5: Global – mAb Biosimilars Market (Million US$), 2016 & 2022
Figure 5-6: Global – Insulin Biosimilars Market (Million US$), 2016 & 2022
Figure 5-7: Global – Interferon Biosimilars Market (Million US$), 2016 & 2022
Figure 5-8: Global – Other Biosimilars Market (Million US$), 2016 & 2022
Figure 6-1: Global – Biosimilars Market by Key Geographies (%), 2016
Figure 6-2: Europe – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-3: Europe – Biosimilars Market by Country (%), 2016
Figure 6-4: Germany – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-5: France – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-6: Italy – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-7: Spain – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-8: UK – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-9: Asia Pacific – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-10: Asia-Pacific – Biosimilars Market by Country (%), 2016
Figure 6-11: India – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-12: China – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-13: Japan – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-14: North America – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-15: North America – Biosimilars Market by Country (%), 2016
Figure 6-16: US – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-17: Canada – Biosimilars Market (Million US$), 2016 & 2022
Figure 6-18: Rest of the World – Biosimilars Market (Million US$), 2016 & 2022
Figure 7-1: Global – Biosimilars Market by Applications (%), 2016
Figure 7-2: Global – Number of New Cancer Cases (Million), 2015 & 2025
Figure 7-3: Oncology – Biosimilars Market (Million US$), 2016 & 2022
Figure 7-4: Blood Disorders – Biosimilars Market (Million US$), 2016 & 2022
Figure 7-5: Other Diseases – Biosimilars Market (Million US$), 2016 & 2022
Figure 11-1: Market Share of Major Players in the Biosimilar Industry, 2015

List of Tables:

Table 5-1: Global – Biosimilar EPOs Approved for Marketing
Table 5-2: Global – Biosimilar EPOs in Pipeline
Table 5-3: Global – Biosimilar HGH Approved for Marketing
Table 5-4: Global – Biosimilar HGH in Pipeline
Table 5-5: Global – Biosimilar G-CSF Approved for Marketing
Table 5-6: Global – Biosimilar G-CSF in Pipeline
Table 5-7: Global – Biosimilar mAbs Approved for Marketing
Table 5-8: Global – Biosimilar mAbs in Pipeline
Table 5-9: Global – Biosimilar Insulin Approved for Marketing
Table 5-10: Global – Biosimilar Insulin in Pipeline
Table 5-11: Global – Biosimilar Interferons Approved for Marketing
Table 5-12: Global – Biosimilar Interferons in Pipeline
Table 9-1: Global – Major M&A in the Biosimilar Industry (2014-2016)
Table 11-1: Biocad – Major Biosimilars Approved for Marketing
Table 11-2: Biocad – Major Biosimilars in Pipeline
Table 11-3: Celltrion Inc. – Revenue (Million US$), 2013, 2014 & 2015
Table 11-4: Celltrion Inc. – Major Biosimilars Approved for Marketing
Table 11-5: Celltrion Inc. – Major Biosimilars in Pipeline
Table 11-6: Dong-A Socio Group – Revenue (Million US$), 2013, 2014 & 2015
Table 11-7: Dong-A Socio Group – Major Biosimilars in Pipeline
Table 11-8: Pfizer Inc. – Revenue (Million US$), 2013, 2014 & 2015
Table 11-9: Pfizer Inc. – Major Biosimilars Approved for Marketing
Table 11-10: Pfizer Inc. – Major Biosimilars in Pipeline
Table 11-11: Intas Pharmaceutical Ltd. – Revenue (Million US$), FY2013, FY2014 & FY2015
Table 11-12: Intas Pharmaceuticals Ltd. – Major Biosimilars Approved for Marketing
Table 11-13: Intas Pharmaceuticals Ltd. – Major Biosimilars in Pipeline
Table 11-14: Sandoz International GmbH – Revenue (Million US$), 2013, 2014 & 2015
Table 11-15: Sandoz International GmbH – Major Biosimilars Approved for Marketing
Table 11-16: Sandoz International GmbH – Major Biosimilars in Pipeline
Table 11-17: Stada Arzneimittel AG – Group Sales (Million US$), 2013, 2014 & 2015
Table 11-18: Stada Arzneimittel AG – Major Biosimilars Approved for Marketing
Table 11-19: Stada Arzneimittel AG – Major Biosimilars in Pipeline
Table 11-20: Teva Pharmaceutical Industries Ltd. – Net Sales (Million US$), 2013, 2014 & 2015
Table 11-21: Teva Pharmaceutical Industries Ltd. – Major Biosimilars Approved for Marketing
Table 11-22: Amgen Inc. – Total Company Revenue (Million US$), 2013, 2014 & 2015
Table 11-23: Amgen Inc. – Major Biosimilars in Pipeline
Table 11-24: Biocon – Revenue (Million US$), FY2014, FY2015 & FY2016
Table 11-25: Biocon – Major Biosimilars Approved for Marketing
Table 11-26: Biocon – Major Biosimilars in Pipeline



【レポートのキーワード】

バイオシミラー、エリスロポエチン(EPO)、ヒト成長ホルモン(HGH)、顆粒球コロニー刺激因子(G-CSF)、モノクローナル抗体(mAb)、インスリン、インターフェロン(IFN)

★調査レポート[バイオシミラーの世界市場見通し2022:エリスロポエチン(EPO)、ヒト成長ホルモン(HGH)、顆粒球コロニー刺激因子(G-CSF)、モノクローナル抗体(mAb)、インスリン、インターフェロン(IFN)] (コード:DATA1122049)販売に関する免責事項を必ずご確認ください。
★調査レポート[バイオシミラーの世界市場見通し2022:エリスロポエチン(EPO)、ヒト成長ホルモン(HGH)、顆粒球コロニー刺激因子(G-CSF)、モノクローナル抗体(mAb)、インスリン、インターフェロン(IFN)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆